InvestSMART

Zelira Therapeutics Limited (ASX:ZLD)

ALERT: Price-sensitive ASX Announcement for ZLD
Current share price for ZLD : $0.500 0.14 (38.89%)+
Announcement
Release
16 Jan 2026 10:03AM
Price at Release
$0.360
Full Release
download
Summary
Zelira Therapeutics Limited has announced a transformative fundraising of US$33 million into its HOPE® 1 Special Purpose Vehicle (SPV), partnering with ThirdGate Capital. The fundraising will provide the necessary capital to complete the accelerated regulatory pathway strategy, utilizing the FDA's 505(b)(2) pathway. This strategic move is aimed at revolutionizing treatment for individuals with autism, starting with Phelan-McDermid Syndrome. The SPV, established in 2023, will finance clinical trials and commercialization of HOPE® 1 in the U.S., with Zelira holding a 39.70% equity stake following the fundraising. The FDA has endorsed the SPV's clinical plan, allowing Zelira to seek orphan drug designation, thus offering regulatory incentives. The fundraising represents a major endorsement of Zelira's vision and science, with Zelira and ThirdGate Capital driving the development forward.
Key Points
  • Zelira Therapeutics raises US$33 million in transformative fundraising.
  • Partnership with ThirdGate Capital to advance HOPE® 1 SPV.
  • Funding supports the FDA's 505(b)(2) pathway strategy.
  • Focus on revolutionizing autism treatment, starting with Phelan-McDermid Syndrome.
  • SPV established to finance clinical trials and commercialization in the U.S.
  • Zelira holds a 39.70% equity stake post-fundraising.
  • FDA endorses clinical plan and orphan drug designation sought.
  • Significant endorsement of Zelira's vision and potential of HOPE® 1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.